Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher Mullard

Showing results (141-150 of 684) with videos related to

Pageof 69
Sort By:
Nature Reviews. Drug Discovery|November 3, 2021
Novartis's canakinumab stumbles in cancer, againAsher Mullard
Nature Reviews. Drug Discovery|April 9, 2022
Engineered IL-2 cytokine takes pivotal immuno-oncology blowAsher Mullard
Nature Reviews. Drug Discovery|April 11, 2023
Pfizer bets big on ADCs with $43-billion Seagen acquisitionAsher Mullard
Nature Reviews. Drug Discovery|April 21, 2021
Long COVID's long R&D agendaAsher Mullard
Nature Reviews. Drug Discovery|June 18, 2026
Multispecific T-cell engagers attract cancer drug developersAsher Mullard
Nature Reviews. Drug Discovery|November 12, 2021
The importance of persistence in cancer drug developmentAsher Mullard
Nature Reviews. Drug Discovery|November 17, 2018
FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years onAsher Mullard
Nature Reviews. Drug Discovery|April 3, 2019
Roche, Biogen and AbbVie stake new gene therapy claimsAsher Mullard
Nature Reviews. Drug Discovery|March 26, 2019
Remyelination researchers regroup after proof-of-concept setback in multiple sclerosisAsher Mullard
Nature Reviews. Drug Discovery|January 14, 2021
FDA outlines steps for individualized drug developmentAsher Mullard
Pageof 69

Showing results (141-150 of 684) with videos related to

Sort By:
Pageof 69
Nature Reviews. Drug Discovery|November 3, 2021
Novartis's canakinumab stumbles in cancer, againAsher Mullard
Nature Reviews. Drug Discovery|April 9, 2022
Engineered IL-2 cytokine takes pivotal immuno-oncology blowAsher Mullard
Nature Reviews. Drug Discovery|April 11, 2023
Pfizer bets big on ADCs with $43-billion Seagen acquisitionAsher Mullard
Nature Reviews. Drug Discovery|April 21, 2021
Long COVID's long R&D agendaAsher Mullard
Nature Reviews. Drug Discovery|June 18, 2026
Multispecific T-cell engagers attract cancer drug developersAsher Mullard
Nature Reviews. Drug Discovery|November 12, 2021
The importance of persistence in cancer drug developmentAsher Mullard
Nature Reviews. Drug Discovery|November 17, 2018
FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years onAsher Mullard
Nature Reviews. Drug Discovery|April 3, 2019
Roche, Biogen and AbbVie stake new gene therapy claimsAsher Mullard
Nature Reviews. Drug Discovery|March 26, 2019
Remyelination researchers regroup after proof-of-concept setback in multiple sclerosisAsher Mullard
Nature Reviews. Drug Discovery|January 14, 2021
FDA outlines steps for individualized drug developmentAsher Mullard
Pageof 69